Evidence map›Paper›PMID 42010117›Full record

Trial reportNature medicine2026

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Omar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, Anna Bosch-Vilaseca, Elizabeth O'Donnell, Robert Redd, Kevin C DeBraganca, Adam S Sperling, Yuxin Liu, Caleb McEntire and 32 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. CAR T cells take on precancers.Nature medicine · 2026
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Omar Nadeem *Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4124-4277
David M Cordas Dos Santos *Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9198-8338
Sarah NikiforowDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Anna Bosch-VilasecaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Elizabeth O'DonnellCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Robert ReddDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Kevin C DeBragancaJanssen Research & Development, Raritan, NJ, USA.
Adam S SperlingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9369-4413
Yuxin LiuCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Caleb McEntireBrigham and Women's Hospital, Boston, MA, USA.
Frances ArtersCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Colin O'DonnellImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Brendan KineavyImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Marjorie MartoCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Amy BergeronCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Emilie SwensonImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Kristin McHughImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Abigail CaronImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Quentin BerryImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Hope WeiImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0028-9572
Emily DurlacherImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7327-9140
Elizabeth GrimmImmune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Francesco CorradoCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Nayda BidikianCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Rocio Montes de OcaJohnson & Johnson, Spring House, PA, USA.
Tamar LengilJohnson & Johnson, Raritan, NJ, USA.
Denise De WiestJohnson & Johnson, Raritan, NJ, USA.
Casey GervaisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kevin PanaroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0004-7430-1399
Eric L SmithDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0296-7587
Kenneth AndersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6418-0886
Caron JacobsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nikhil C MunshiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7344-9795
Paul RichardsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Deepu MadduriJohnson & Johnson, Raritan, NJ, USA.
Jordan M SchecterJohnson & Johnson, Raritan, NJ, USA.
Craig TendlerJohnson & Johnson, Raritan, NJ, USA.
Mark A WildgustJohnson & Johnson, Raritan, NJ, USA.
Lorenzo TrippaDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Maria Victoria MateosInstituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.ORCID http://orcid.org/0000-0003-2390-1218
Jerome RitzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5526-4669
Irene M GhobrialCenter for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7361-3092

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 525171148
6 · The paper itself

Abstract

High-risk smoldering multiple myeloma (HR-SMM) carries an increased risk of progression to multiple myeloma, making it an ideal setting to test whether chimeric antigen receptor (CAR) T cell therapy can achieve curative outcomes. Here in this phase 2 study, patients with HR-SMM received ciltacabtagene autoleucel (cilta-cel) at 0.3-0.5 × 10

Indexed as

Immunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenSmoldering Multiple MyelomaAgedFemaleHumansMaleMiddle AgedNeoplasm, ResidualReceptors, Chimeric Antigen

Identifiers

PMID42010117
PMCPMC13375535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.